MoonLake Immunotherapeutics is a Swiss biopharmaceutical company leveraging single-domain antibody (Nanobody®) technology to develop medicines for immunologic diseases, including inflammatory skin and joint diseases.
Nanobodies® are proprietary therapeutic proteins based on single-domain antibody fragments, with the benefits of conventional antibodies but at 1/10th the size. MoonLake has licensed Merck KGaA’s phase 3-ready drug sonelokimab (M1095) (originally discovered by Ablynx), an IL-17A/IL-17F inhibitor with an albumin binding site, which has the potential to facilitate deep tissue penetration in the skin and joints.
MoonLake was founded in 2021 and plans to accelerate the development of Sonelokimab in multiple inflammatory diseases in dermatology and rheumatology driven by IL-17A and IL-17F. This group of IL-17A/F Inflammatory Diseases includes psoriatic arthritis, ankylosing spondylitis, and hidradenitis suppurativa. MoonLake says it plans to initiate multiple Phase 2 trials soon.
The company recently published Phase 2b data in The Lancet showing Sonelokimab totally clears skin in almost 6 out of 10 patients with moderate to severe psoriasis.
MoonLake aims to develop Sonelokimab in multiple indications through to commercialization, potentially in partnership with established biopharma companies.
Subscribe for alerts on new companies featured on Startups.Bio
The biotechnology sector is advancing rapidly, fueled by significant venture capital investments that are enabling companies to achieve major breakthroughs. To stay informed about the …
Founded in 2024, Analona Therapeutics is a biotech company located in Denmark focused on developing innovative antibody-based therapies for pancreatic cancer. The company is built …
U-Ploid Biotechnologies aims to revolutionize IVF for Age-Related Infertility. Millions of women around the world face the emotional and financial toll of age-related infertility. As …
BioTryp Therapeutics is University of Cambridge spin-out biotechnology company that focuses on the development of small molecules to inhibit biofilm formation, which causes 80% of …
Bastion Therapeutics is a pre-clinical stage biotechnology company focused on developing best-in-class Treg cell therapies, which can target the root causes of inflammatory disorders and …
HOVANA is a digital biology company tackling translational dysfunction as a driver of serious diseases. Leveraging insights into cellular reprogramming, HOVANA is inventing a new …